医学
无容量
易普利姆玛
内科学
危险系数
肿瘤科
化疗
肺癌
癌症
置信区间
免疫疗法
作者
Arnaud Scherpereel,Scott Antonia,Y. Bautista,Francesco Grossi,Dariusz M. Kowalski,Gérard Zalcman,Anna K. Nowak,Nobukazu Fujimoto,Solange Peters,Anne S. Tsao,Aaron S. Mansfield,Sanjay Popat,Xiaowu Sun,Rachael Lawrance,Xiaoqing Zhang,M. Daumont,Bryan Bennett,Mike McKenna,Paul Baas
出处
期刊:Lung Cancer
[Elsevier BV]
日期:2022-03-21
卷期号:167: 8-16
被引量:31
标识
DOI:10.1016/j.lungcan.2022.03.012
摘要
Nivolumab + ipilimumab decreased the risk of deterioration in disease-related symptoms and HRQoL versus chemotherapy and maintained QoL in patients with unresectable MPM.
科研通智能强力驱动
Strongly Powered by AbleSci AI